{"organizations": [], "uuid": "2a98721c0b7e1a8f0f24c6a4f1291ef384fac8cc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "news.morningstar.com", "main_image": "", "site_section": "http://news.morningstar.com/all/dow-jones/technology.aspx", "section_title": "News Archive: Technology", "url": "http://news.morningstar.com/all/dow-jones/technology/201509235438/amgen-allergan-biosimilar-lung-cancer-therapy-shows-positive-results.aspx", "country": "US", "title": "Amgen, Allergan Biosimilar Lung-Cancer Therapy Shows Positive Results", "performance_score": 0, "site": "morningstar.com", "participants_count": 1, "title_full": "Amgen, Allergan Biosimilar Lung-Cancer Therapy Shows Positive Results", "spam_score": 0.0, "site_type": "news", "published": "2015-09-23T03:00:00.000+03:00", "replies_count": 0, "uuid": "2a98721c0b7e1a8f0f24c6a4f1291ef384fac8cc"}, "author": "morningstar.com", "url": "http://news.morningstar.com/all/dow-jones/technology/201509235438/amgen-allergan-biosimilar-lung-cancer-therapy-shows-positive-results.aspx", "ord_in_thread": 0, "title": "Amgen, Allergan Biosimilar Lung-Cancer Therapy Shows Positive Results", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "By Tess Stynes\nAmgen Inc. and Allergan PLC said their investigational biosimilar treatment for advanced lung cancer demonstrated clinical equivalence in safety and effectiveness compared with Roche Holding AG's Avastin.\nThe investigational biosimilar for advanced nonsquamous nonsmall cell lung cancer--called ABP 215--is being developed as a biosimilar to bevacizumab, which is marketed under the brand name Avastin.\nAmgen's head of research and development Sean Harper said in prepared remarks Wednesday that nonsmall-cell lung cancer is the leading cause of cancer deaths in the U.S. and the European Union among both men and women.\nThe introduction of biosimilar drugs in the U.S., which kicked off this month with Novartis AG's version of an Amgen Inc. blockbuster, is expected to provide options to battle rising drug prices, which have been drawing increasing criticism.\nAmgen and Allergan are collaborating on four biosimilar cancer treatments while both drug makers are developing biosimilar treatments separately.\nEarlier this year, Amgen's investigational biosimilar treatment for moderate-to-severe rheumatoid arthritis showed clinical equivalence with AbbVie's Humira after 24 weeks in a phase III study.\nWrite to Tess Stynes at tess.stynes@wsj.com\n 23, 2015 10:11 ET (14:11 ", "external_links": ["http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Checked.gif", "http://s7.addthis.com/static/btn/sm-share-en.gif", "http://www.addthis.com/bookmark.php?v=250", "http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Unchecked.gif"], "published": "2015-09-23T03:00:00.000+03:00", "crawled": "2015-09-24T01:30:00.179+03:00", "highlightTitle": ""}